Arcus Biosciences unveils ARC‑20 kidney‑cancer data showing strong efficacy across treatment lines
Arcus Biosciences presented new ARC‑20 data for its HIF‑2α inhibitor casdatifan in first‑, second‑ and late‑line clear cell renal cell carcinoma. The data showed 86% 6‑month PFS in first‑line, a 14.5‑month median PFS in second‑line with cabozantinib, and a 35‑month median overall survival in heavily pre‑treated patients. The company said the results support initiating the registrational PEAK‑20 first‑line trial and a later‑line trial with tivozanib by year‑end.
Why it matters
The data suggest casdatifan could become a backbone therapy for RCC, expanding Arcus' addressable market and potentially driving future revenue if the upcoming Phase 3 trials confirm efficacy. Investors will watch enrollment progress in PEAK‑20 and PEAK‑1 as the next catalysts.
Key facts
- 1The ARC‑20 data cut‑off was September 4, 2026. stocktitan.net
- 2First‑line casdatifan + zimberelimab achieved 86% 6‑month PFS and 69% 12‑month PFS (n=30). stocktitan.net
- 3First‑line confirmed objective response rate was 50% with 6.7% primary progression. stocktitan.net
- 4Second‑line casdatifan + cabozantinib showed a 14.5‑month median PFS and 77% 18‑month OS (n=43). stocktitan.net
- 5Late‑line casdatifan monotherapy yielded a 35‑month median overall survival. stocktitan.net
- 6Arcus plans to start the PEAK‑20 first‑line registrational trial by the end of 2026. stocktitan.net
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.